Mayne Pharma Group Ltd
ASX:MYX

Watchlist Manager
Mayne Pharma Group Ltd Logo
Mayne Pharma Group Ltd
ASX:MYX
Watchlist
Price: 4.48 AUD 7.18% Market Closed
Market Cap: 381.1m AUD
Have any thoughts about
Mayne Pharma Group Ltd?
Write Note

Intrinsic Value

The intrinsic value of one MYX stock under the Base Case scenario is 8.43 AUD. Compared to the current market price of 4.48 AUD, Mayne Pharma Group Ltd is Undervalued by 47%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

MYX Intrinsic Value
8.43 AUD
Undervaluation 47%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Mayne Pharma Group Ltd

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for MYX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about MYX?
Bearish
Neutral
Bullish

Fundamental Analysis

Economic Moat
Mayne Pharma Group Ltd

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Mayne Pharma Group Ltd

Provide an overview of the primary business activities
of Mayne Pharma Group Ltd.

What unique competitive advantages
does Mayne Pharma Group Ltd hold over its rivals?

What risks and challenges
does Mayne Pharma Group Ltd face in the near future?

Has there been any significant insider trading activity
in Mayne Pharma Group Ltd recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Mayne Pharma Group Ltd.

Provide P/S
for Mayne Pharma Group Ltd.

Provide P/E
for Mayne Pharma Group Ltd.

Provide P/OCF
for Mayne Pharma Group Ltd.

Provide P/FCFE
for Mayne Pharma Group Ltd.

Provide P/B
for Mayne Pharma Group Ltd.

Provide EV/S
for Mayne Pharma Group Ltd.

Provide EV/GP
for Mayne Pharma Group Ltd.

Provide EV/EBITDA
for Mayne Pharma Group Ltd.

Provide EV/EBIT
for Mayne Pharma Group Ltd.

Provide EV/OCF
for Mayne Pharma Group Ltd.

Provide EV/FCFF
for Mayne Pharma Group Ltd.

Provide EV/IC
for Mayne Pharma Group Ltd.

Show me price targets
for Mayne Pharma Group Ltd made by professional analysts.

What are the Revenue projections
for Mayne Pharma Group Ltd?

How accurate were the past Revenue estimates
for Mayne Pharma Group Ltd?

What are the Net Income projections
for Mayne Pharma Group Ltd?

How accurate were the past Net Income estimates
for Mayne Pharma Group Ltd?

What are the EPS projections
for Mayne Pharma Group Ltd?

How accurate were the past EPS estimates
for Mayne Pharma Group Ltd?

What are the EBIT projections
for Mayne Pharma Group Ltd?

How accurate were the past EBIT estimates
for Mayne Pharma Group Ltd?

Compare the revenue forecasts
for Mayne Pharma Group Ltd with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Mayne Pharma Group Ltd and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Mayne Pharma Group Ltd against its competitors.

Analyze the profit margins
(gross, operating, and net) of Mayne Pharma Group Ltd compared to its peers.

Compare the P/E ratios
of Mayne Pharma Group Ltd against its peers.

Discuss the investment returns and shareholder value creation
comparing Mayne Pharma Group Ltd with its peers.

Analyze the financial leverage
of Mayne Pharma Group Ltd compared to its main competitors.

Show all profitability ratios
for Mayne Pharma Group Ltd.

Provide ROE
for Mayne Pharma Group Ltd.

Provide ROA
for Mayne Pharma Group Ltd.

Provide ROIC
for Mayne Pharma Group Ltd.

Provide ROCE
for Mayne Pharma Group Ltd.

Provide Gross Margin
for Mayne Pharma Group Ltd.

Provide Operating Margin
for Mayne Pharma Group Ltd.

Provide Net Margin
for Mayne Pharma Group Ltd.

Provide FCF Margin
for Mayne Pharma Group Ltd.

Show all solvency ratios
for Mayne Pharma Group Ltd.

Provide D/E Ratio
for Mayne Pharma Group Ltd.

Provide D/A Ratio
for Mayne Pharma Group Ltd.

Provide Interest Coverage Ratio
for Mayne Pharma Group Ltd.

Provide Altman Z-Score Ratio
for Mayne Pharma Group Ltd.

Provide Quick Ratio
for Mayne Pharma Group Ltd.

Provide Current Ratio
for Mayne Pharma Group Ltd.

Provide Cash Ratio
for Mayne Pharma Group Ltd.

What is the historical Revenue growth
over the last 5 years for Mayne Pharma Group Ltd?

What is the historical Net Income growth
over the last 5 years for Mayne Pharma Group Ltd?

What is the current Free Cash Flow
of Mayne Pharma Group Ltd?

Discuss the annual earnings per share (EPS)
trend over the past five years for Mayne Pharma Group Ltd.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
Mayne Pharma Group Ltd

Balance Sheet Decomposition
Mayne Pharma Group Ltd

Current Assets 460.6m
Cash & Short-Term Investments 151.6m
Receivables 207.7m
Other Current Assets 101.3m
Non-Current Assets 682.6m
PP&E 53.3m
Intangibles 568.6m
Other Non-Current Assets 60.7m
Current Liabilities 313.9m
Accounts Payable 20.9m
Accrued Liabilities 179.9m
Other Current Liabilities 113.2m
Non-Current Liabilities 375.1m
Long-Term Debt 35m
Other Non-Current Liabilities 340.1m
Efficiency

Earnings Waterfall
Mayne Pharma Group Ltd

Revenue
395.5m AUD
Cost of Revenue
-169.6m AUD
Gross Profit
225.8m AUD
Operating Expenses
-381.1m AUD
Operating Income
-155.3m AUD
Other Expenses
-18.9m AUD
Net Income
-174.2m AUD

Free Cash Flow Analysis
Mayne Pharma Group Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

MYX Profitability Score
Profitability Due Diligence

Mayne Pharma Group Ltd's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional 1-Year Revenue Growth
Positive Revenue Growth Forecast
Negative ROIC
29/100
Profitability
Score

Mayne Pharma Group Ltd's profitability score is 29/100. The higher the profitability score, the more profitable the company is.

MYX Solvency Score
Solvency Due Diligence

Mayne Pharma Group Ltd's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Low D/E
Long-Term Solvency
Short-Term Solvency
56/100
Solvency
Score

Mayne Pharma Group Ltd's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MYX Price Targets Summary
Mayne Pharma Group Ltd

Wall Street analysts forecast MYX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MYX is 6.21 AUD with a low forecast of 5.99 AUD and a high forecast of 6.56 AUD.

Lowest
Price Target
5.99 AUD
34% Upside
Average
Price Target
6.21 AUD
39% Upside
Highest
Price Target
6.56 AUD
46% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for MYX?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for MYX is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

MYX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Mayne Pharma Group Ltd Logo
Mayne Pharma Group Ltd

Country

Australia

Industry

Pharmaceuticals

Market Cap

364m AUD

Dividend Yield

0.61%

Description

Mayne Pharma Group Ltd. engages in the development and manufacture of proprietary and generic products. The company is headquartered in Adelaide, South Australia. The company went IPO on 2007-06-29. The Company’s segments include Generic Products (GPD), Specialty Products (SPD), Metrics Contract Services (MCS), and Mayne Pharma International (MPI). The GPD segment is engaged in the distribution of generic pharmaceutical products in the United States. GPD segment engaged in the distribution of generic pharmaceutical products in the United States. MCS segment is providing contract pharmaceutical development and manufacturing services to third party customers principally in the United States. SPD segment is distributing specialty pharmaceutical products in the United States. MPI segment manufactures and sells branded and generic pharmaceutical products globally and provisions of contract manufacturing services to third party customers within Australia.

Contact

SOUTH AUSTRALIA
Adelaide
1538 Main North Rd
+61882092666.0
www.maynepharma.com

IPO

2007-06-29

Employees

-

Officers

CEO, MD & Director
Mr. Shawn Patrick O'Brien B.Sc
Chief Financial Officer
Mr. Aaron Gray
Executive VP & General Counsel
Ms. Kimberly Parker J.D.
Executive Vice President of Corporate Development
Mr. Brant Schofield
Director of Global Human Resources
Ms. Erinn Nathaniel
Executive Vice President of Commercial
Mr. Daniel Moore
Show More
Executive VP & Global Chief Medical Officer
Dr. Frank Casty M.D.
Financial Controller
Mr. Brenton Walter
Associate General Counsel & Company Secretary
Ms. Laura Loftus
Show Less

See Also

Discover More
What is the Intrinsic Value of one MYX stock?

The intrinsic value of one MYX stock under the Base Case scenario is 8.43 AUD.

Is MYX stock undervalued or overvalued?

Compared to the current market price of 4.48 AUD, Mayne Pharma Group Ltd is Undervalued by 47%.

Back to Top